ReviewThe Yale journal of biology and medicine2016
Neurodegeneration and Neuroprotection in Glaucoma.
Review in The Yale journal of biology and medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Uric acid and glaucoma: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Article
- Ferroptosis and retinal ganglion cell death in glaucoma: Mechanisms and therapeutic approaches.Journal of pharmaceutical analysis · 2026Review
- Hippocampal subregions functional connectivity alterations in primary angle-closure glaucoma patients with cognitive dysfunction: a resting-state fMRI study.BMC neurology · 2025Article
- Leveraging Alzheimer's Disease Omics to Identify Pleiotropic Genes Contributing to Neurodegeneration in Primary Open-Angle Glaucoma.Molecular neurobiology · 2025Article
- HOCPCA Exerts Neuroprotection on Retinal Ganglion Cells by Binding to CaMKIIα and Modulating Oxidative Stress and Neuroinflammation in Experimental Glaucoma.Neuroscience bulletin · 2025Article
- Associations Between Cerebral Perfusion Pressure, Hemodynamic Parameters, and Cognitive Test Values in Normal-Tension Glaucoma Patients, Alzheimer's Disease Patients, and Healthy Controls.Medicina (Kaunas, Lithuania) · 2025Article
- Development of a Liposome Nanoformulation for the Delivery of Lipoic Acid as a Potential Neuroprotective Therapy in Glaucoma.Pharmaceutics · 2025Article
- Mechanisms of Erythropoietin-Mediated Protection Against Retinal Ganglion Cell Apoptosis.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model.Drug delivery and translational research · 2025Article
- Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana.PLOS global public health · 2025Article
- Glaucoma: Current and New Therapeutic Approaches.Biomedicines · 2024Review
- Aging and "Age-Related" Diseases - What Is the Relation?Aging and disease · 2024Review
- Obesity, body fat distribution and eye diseases.Eating and weight disorders : EWD · 2024Review
- Modeling complex age-related eye disease.Progress in retinal and eye research · 2024Review
- Exploring Epigenetic Modifications as Potential Biomarkers and Therapeutic Targets in Glaucoma.International journal of molecular sciences · 2024Review
- The concept of gene therapy for glaucoma: the dream that has not come true yet.Neural regeneration research · 2024Review
- Preventive Effects of Crocin, a Key Carotenoid Component in Saffron, Against Nicotine-Triggered Neurodegeneration in Rat Hippocampus: Possible Role of Autophagy and Apoptosis.International journal of preventive medicine · 2024Article
- Metabolic syndrome as an independent risk factor for glaucoma: a nationally representative study.Diabetology & metabolic syndrome · 2023Article
- Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease even shares some characteristics with other central nervous system degenerative disorders. Glaucoma destroys neurons through oxidative stress, impairment in axonal transport, neuroinflammation, and excitotoxicity. Autophagy may promote or inhibit disease progression. Currently, lowering intraocular pressure is the only way proven to delay glaucoma advancement. However, many new therapies are being developed, including antioxidants, adenosine receptor antagonists, Rho-pathway inhibitors, stem cell therapy, and neurotrophic factors. These therapies focus on neuroprotection, and they may eventually halt glaucoma progression or reverse the process of the disease itself.
Indexed as
Identifiers
27505018PMC4797839W2413982824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.